The stock of Aardvark Therapeutics Inc (AARD) has seen a 7.00% increase in the past week, with a 15.82% gain in the past month, and a 25.96% flourish in the past quarter. The volatility ratio for the week is 4.20%, and the volatility levels for the past 30 days are at 4.33% for AARD. The simple moving average for the past 20 days is 9.13% for AARD’s stock, with a 16.54% simple moving average for the past 200 days.
Is It Worth Investing in Aardvark Therapeutics Inc (NASDAQ: AARD) Right Now?
There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AARD is 12.39M, and at present, short sellers hold a 2.77% of that float. The average trading volume of AARD on June 20, 2025 was 78.97K shares.
AARD) stock’s latest price update
Aardvark Therapeutics Inc (NASDAQ: AARD)’s stock price has plunge by 7.19relation to previous closing price of 11.27. Nevertheless, the company has seen a 7.00% surge in its stock price over the last five trading sessions. zacks.com reported 2025-06-03 that The mean of analysts’ price targets for Aardvark Therapeutics, Inc. (AARD) points to an 180.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Analysts’ Opinion of AARD
Many brokerage firms have already submitted their reports for AARD stocks, with RBC Capital Mkts repeating the rating for AARD by listing it as a “Outperform.” The predicted price for AARD in the upcoming period, according to RBC Capital Mkts is $21 based on the research report published on March 10, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see AARD reach a price target of $29. The rating they have provided for AARD stocks is “Overweight” according to the report published on March 10th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to AARD, setting the target price at $50 in the report published on March 10th of the current year.
AARD Trading at 20.78% from the 50-Day Moving Average
After a stumble in the market that brought AARD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.30% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AARD starting from Decheng Capital Global Life Sc, who purchase 1,250,000 shares at the price of $16.00 back on Feb 14 ’25. After this action, Decheng Capital Global Life Sc now owns 2,958,887 shares of Aardvark Therapeutics Inc, valued at $20,000,000 using the latest closing price.
Lee Tien-Li, the Chief Executive Officer of Aardvark Therapeutics Inc, purchase 16,542 shares at $16.00 during a trade that took place back on Feb 14 ’25, which means that Lee Tien-Li is holding 1,496,175 shares at $264,672 based on the most recent closing price.
Stock Fundamentals for AARD
The total capital return value is set at -0.18. Equity return is now at value -110.36, with -46.77 for asset returns.
Based on Aardvark Therapeutics Inc (AARD), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -33.37.
Currently, EBITDA for the company is -22.79 million with net debt to EBITDA at 0.96. The liquidity ratio also appears to be rather interesting for investors as it stands at 25.86.
Conclusion
In summary, Aardvark Therapeutics Inc (AARD) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
